
News|Articles|December 24, 2025
The Hidden Cost of Health Misinformation
Author(s)Lana Pine
Fact checked by: Patrick Campbell
Clinicians across specialties explain how health misinformation is reshaping patient decisions, delaying care, and undermining trust.
Advertisement
Advertisement
Health information is everywhere. Patients can look up symptoms, medications, side effects, and treatment options in seconds before they ever speak with a clinician. While this access has empowered many people to take a more active role in their health, clinicians across specialties say it has also created a serious and growing challenge: health misinformation that shapes decisions, delays care, and undermines trust.
Related to this article

The Liver Keeps the Score: Americans Are Drinking Less, but Alcohol-Associated Liver Disease May Lag
Drinking fell for the first time since COVID-19, but not for adults 50 to 64. Hepatologists explain what clinicians can do to close the gap.

As drinking declines, Stevan Gonzalez, MD, Frances Lee, MD, and Brian Lee, MD, on the lingering burden of alcohol-associated liver disease.

Patients with obesity or overweight and T2D saw substantially greater mean weight loss and HbA1c improvement with petrelintide versus placebo.

Remibrutinib doubled complete Total Fric Score response vs placebo at week 12 in RemIND, becoming the first therapy approved specifically for SD.

Presented at EASD 2026, the present analysis discusses CBL-514’s apparent efficacy in reducing L2-L3 visceral fat compared to placebo.

A hepatologist on the lag between drinking and liver disease, metabolic risk, prevention gaps, and when the burden may peak.

Nephrology in Q3 2026: FDA approvals for atacicept, iptacopan, finerenone, and obinutuzumab, plus 2-year IgAN data and CKD screening.
Advertisement
Advertisement

